Shield Therapeutics (STX) AI Stock Analysis

• Market Cap: £47.92M
• Dividend Yield: N/A
• Average Volume (3M): 2.56M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.84
• Revenue Growth: 139.31%
• EPS Growth: 26.49%
• Country: UK
• Employees: 63
• Sector: Healthcare
• Sector Strength: 37
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.01
• Shares Outstanding: 1,041,690,400
• 10 Day Avg. Volume: 2,505,012
• 30 Day Avg. Volume: 2,562,158
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £2.50
• Price Target Upside: -44.44% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 61 Neutral
• Price Target: 5.00p ▲(11.11% Upside)

The overall score is driven by robust technical analysis signals and positive corporate events, indicating potential for future growth. However, severe financial distress and high-risk valuation significantly dampen the overall score, highlighting substantial challenges that need to be addressed.

Positive Factors

Cash Flow

$6.5m of cash plus successful $10m raise with AOP Health does provide some much-needed breathing room for Shield in 2025.

Prescription Coverage

The percentage of non-covered prescriptions dropped from 37% to 22%, contributing to the revenue growth.

Revenue Growth

The significant increase in NSP in 4Q24 to $237 supported Shield delivering $32.2m in revenues for 2024, slightly ahead of expectations.

Negative Factors

Cash Flow Timing

The timing at which Shield becomes cash flow positive may be delayed beyond 2025, with negative script growth being a concern.

Script Growth

Negative script growth in Q4 and a potentially soft 1Q25 driven by usual insurance renewals and unwind of year-end stocking is a concern.

Shield Therapeutics Business Overview & Revenue Model

Company Description

Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company was founded in 2008 and is based in Gateshead, the United Kingdom.

How the Company Makes Money

Shield Therapeutics generates revenue through the commercialization of its primary product, Feraccru®/Accrufer®. The company earns money by selling this product to healthcare providers, hospitals, and through distribution partners. Revenue streams include direct sales in markets where it has regulatory approval and licensing agreements with other pharmaceutical companies for distribution rights in different regions. Strategic partnerships play a significant role in expanding its market reach and enhancing sales, contributing to the company's earnings.

Shield Therapeutics Financial Statement Overview

Summary

Despite robust revenue growth, the company struggles with persistent negative profitability, negative equity, and cash flow issues, indicating financial distress and high leverage risk.

Income Statement

The company has shown significant revenue growth, with total revenue increasing from 1.5 million in 2021 to 25.2 million in 2024, representing a strong growth trajectory. However, the net profit margin remains deeply negative due to substantial net losses, and both EBIT and EBITDA margins are negative, indicating ongoing operational challenges and profitability issues.

Balance Sheet

The balance sheet reflects a negative stockholders' equity as of 2024, indicating financial distress and a potential risk of insolvency. The debt-to-equity ratio is high due to negative equity, and the equity ratio is also negative, highlighting a critical situation in terms of financial stability and leverage.

Cash Flow

Free cash flow remains negative, although there is a small improvement in operating cash flow. The free cash flow to net income ratio is negative, indicating cash flow problems. However, the company has managed to reduce the magnitude of negative operating cash flow compared to previous years, showing a slight improvement in cash management.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	25.18M	13.09M	4.47M	1.52M	10.39M
Gross Profit	10.57M	4.03M	2.00M	539.00K	9.03M
EBITDA	-16.58M	-30.29M	-37.39M	-17.35M	820.00K
Net Income	-21.27M	-33.29M	-40.44M	-19.34M	-2.63M
Balance Sheet
Total Assets	45.90M	48.80M	22.07M	44.41M	32.53M
Cash, Cash Equivalents and Short-Term Investments	5.61M	13.95M	2.82M	12.12M	2.94M
Total Debt	21.06M	20.25M	6.10M	156.00K	28.00K
Total Liabilities	46.95M	33.77M	16.65M	3.38M	2.25M
Stockholders Equity	-1.05M	11.79M	5.43M	41.03M	30.28M
Cash Flow
Free Cash Flow	-7.03M	-40.07M	-20.14M	-18.80M	-1.42M
Operating Cash Flow	-7.01M	-37.13M	-18.25M	-16.74M	-1.40M
Investing Cash Flow	-1.89M	-2.43M	-1.70M	-2.05M	-20.00K
Financing Cash Flow	4.21M	49.66M	7.71M	27.58M	-47.00K

Shield Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.50
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:STX, the sentiment is Positive. The current price of 4.5 is above the 20-day moving average (MA) of 4.18, above the 50-day MA of 3.26, and above the 200-day MA of 2.96, indicating a bullish trend. The MACD of 0.42 indicates Positive momentum. The RSI at 71.58 is Negative, neither overbought nor oversold. The STOCH value of 39.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:STX.

Shield Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HIK	71 Outperform	£4.15B	14.54	15.66%	3.54%	3.73%	27.13%
ANCR	68 Neutral	£186.96M	34.70	5.04%	1.85%	-0.17%	592.46%
STX	61 Neutral	£47.92M	―	-396.71%	―	139.31%	26.49%
AGY	56 Neutral	£381.32M	―	-369.20%	―	4.50%	74.32%
Sector *	50 Neutral	AU$2.60B	3.64	-58.14%	2.69%	36.37%	13.78%

Shield Therapeutics Corporate Events

Shield Therapeutics Doubles ACCRUFeR® Revenues in Q2 2025

Shield Therapeutics reported a significant increase in Q2 2025 net revenues for its product ACCRUFeR®, doubling from Q1 to $12.8 million, with a notable rise in prescriptions and average net selling price. The company’s cash reserves were bolstered by milestone payments from international partners, supporting its trajectory towards cash flow positivity by the end of 2025. This robust performance underscores the growing market adoption of ACCRUFeR® and its potential to become the preferred oral iron therapy for patients with iron deficiency, reinforcing Shield’s strategic market positioning.

The most recent analyst rating on (GB:STX) stock is a Hold with a £2.00 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.

Shield Therapeutics Secures Shareholder Support at 2025 AGM

Shield Therapeutics announced the successful passing of all resolutions at its 2025 Annual General Meeting, indicating strong shareholder support. This development underscores the company’s stable governance and may positively impact its strategic initiatives in the competitive pharmaceutical market, particularly in expanding the reach of its flagship product, ACCRUFeR®/FeRACCRU®.

The most recent analyst rating on (GB:STX) stock is a Hold with a £2.00 price target. To see the full list of analyst forecasts on Shield Therapeutics stock, see the GB:STX Stock Forecast page.